These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37817009)

  • 1. Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD.
    McBride HJ; Frazer-Abel A; Thiemann S; Lehto SG; Hutterer KM; Liu J
    Ann Hematol; 2023 Dec; 102(12):3299-3309. PubMed ID: 37817009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product.
    Hutterer KM; Ip A; Kuhns S; Cao S; Wikström M; Liu J
    BioDrugs; 2021 Sep; 35(5):563-577. PubMed ID: 34296421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method.
    Kim H; Hong E; Lee J; Hong S; Kim J; Cho M; Kim Y; Yoo T
    BioDrugs; 2023 Jul; 37(4):569-581. PubMed ID: 37060541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria.
    Kulasekararaj A; Lanza F; Arvanitakis A; Langemeijer S; Chonat S; Tombak A; Hanes V; Cao J; Miller MJ; Colbert A; Shander B; Mytych DT; Chow V; Henary H
    Am J Hematol; 2024 Nov; 99(11):2108-2117. PubMed ID: 39171864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
    Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
    Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.
    Schmidt CQ; Smith RJH
    Immunol Rev; 2023 Jan; 313(1):376-401. PubMed ID: 36398537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical and functional similarity of biosimilar Elizaria® with eculizumab reference product.
    Gusarova V; Degterev M; Lyagoskin I; Simonov V; Smolov M; Taran S; Shukurov R
    J Pharm Biomed Anal; 2022 Oct; 220():115004. PubMed ID: 35988306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
    J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
    Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris
    Chow V; Pan J; Chien D; Mytych DT; Hanes V
    Eur J Haematol; 2020 Jul; 105(1):66-74. PubMed ID: 32196749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
    Kerboua KE; Haiba F; Batouche D
    J Immunoassay Immunochem; 2017; 38(2):178-189. PubMed ID: 27617501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms.
    Bouwman HB; Guchelaar HJ
    Drug Discov Today; 2024 Sep; 29(9):104134. PubMed ID: 39111540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome].
    Lavrishcheva YV; Yakovenko AA; Kudlai DA
    Ter Arkh; 2020 Jul; 92(6):76-80. PubMed ID: 33346497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Frampton JE
    Drugs; 2020 May; 80(7):719-727. PubMed ID: 32266705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.